The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on July 10, 2018. This approval, categorized under efficacy, indicates that new data supported an expansion of the drug's approved uses or conditions of use.
Background
Nivolumab is a pharmaceutical product developed and marketed by Bristol Myers Squibb, who was the sponsor for this supplemental application. The approval specifically addressed the efficacy of the drug, meaning the FDA evaluated data demonstrating its effectiveness for a particular purpose.
What this means
A supplemental approval for efficacy signifies that the FDA has reviewed additional clinical data and determined that nivolumab is effective for an expanded indication, a new patient population, or under modified conditions of use. While the specific details of this expanded efficacy are not provided in the approval summary, such approvals are crucial for broadening the therapeutic utility of established medications. For clinicians, this means new treatment options or guidelines may become available for patients who could benefit from nivolumab. Researchers may find new avenues for investigation based on the data supporting this expanded efficacy. Patient advocates can use this information to understand the evolving landscape of treatment options, even without the specific indication details. The "efficacy" classification confirms that the approval was based on evidence demonstrating the drug's positive impact on a disease or condition, rather than solely on safety or manufacturing changes.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 125554 S-63, pertaining to Opdivo (nivolumab), was documented on July 10, 2018, on the accessdata.fda.gov website.